Learn About Smoldering Multiple Myeloma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
MD Anderson
Robert Orlowski is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Orlowski is rated as an Elite provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.
Dana-Farber Cancer Institute, Inc.
Paul Richardson is a Hematologist Oncology specialist and an Oncologist in Milford, Massachusetts. Dr. Richardson is rated as an Elite provider by MediFind in the treatment of Smoldering Multiple Myeloma. His top areas of expertise are Multiple Myeloma, Hepatic Venoocclusive Disease with Immunodeficiency, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Graft. Dr. Richardson is currently accepting new patients.
Atrium Health Levine Cancer Institute (Hematology)
Manisha Bhutani is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Bhutani is rated as an Elite provider by MediFind in the treatment of Smoldering Multiple Myeloma. Her top areas of expertise are Smoldering Multiple Myeloma, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bhutani is currently accepting new patients.
Summary: The purpose of this study is to evaluate the real-world characteristics and outcomes of participants with smoldering multiple myeloma (SMM) overall and by high-risk and non-high-risk SMM according to (AQUILA study criteria \[NCT03301220\], Mayo 20-2-20 and international myeloma working group (IMWG) 2020 risk classification models), and to evaluate the risk of progressing of SMM to multiple myeloma...
Summary: The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants i...